SCOTUS upholds Medicare drug price negotiations under IRA
Key Questions
What was the outcome of drugmakers' challenges to Medicare drug price negotiations?
The Supreme Court denied certiorari, upholding the Inflation Reduction Act's Medicare drug price negotiation provisions and protecting lower costs for beneficiaries.
How does the Supreme Court's action affect regulatory power under the IRA?
By declining to hear the challenges, the Court left intact the government's authority to negotiate drug prices, strengthening the program's implementation.
What impact will this have on older adults' prescription drug costs?
The ruling preserves mechanisms that lower out-of-pocket costs for Medicare enrollees by allowing negotiated prices on select high-cost medications.
Cert denial rejects drugmaker challenges protecting lower costs for older adults; cements regulatory power.
Sources (2)
Updated May 20, 2026